Olanzapine in the Treatment of Anorexia Nervosa

Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00592930

Enrollment

Registered

2008-01-14

Start date

2000-06-30

Completion date

2004-12-31

Last updated

2008-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anorexia Nervosa

Keywords

anorexia nervosa, treatment, adolescents, olanzapine

Brief summary

This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.

Interventions

DRUGolanzapine

flexibly dosed oral olanzapine 2.5 to 15 mg/day

DRUGplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

12 Years to 23 Years

Healthy volunteers

Inclusion criteria

* Females, ages 12-23

Exclusion criteria

* Binge-purge type

Design outcomes

Primary

Measure	Time frame
weight gain	10 weeks

Secondary

Measure	Time frame
measures of psychiatric symptoms	10 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026